June 26, 2009
 

Stamina-Rx Dietary Supplement Products


Stamina-Rx Dietary Supplement Products
FDA and Hi-Tech Pharmaceuticals notified patients and healthcare professionals of a nationwide recall of all product sold under the name Stamina-Rx. Hi-Tech was notified by the FDA that the lab analysis of Stamina-Rx samples found that the product contained the undeclared ingredient − benzamidenafil − a Phosphodiesterase Type 5 inhibitor.
Source: www.fda.gov

Antiepileptic Drugs

Source: www.fda.gov

U.S. Attorney News Release: Howard County Pharmacy Owner Indicted for Health Care Fraud
A federal grand jury yesterday indicted Pamela Arrey, age 48, Glenelg, Maryland, for health care fraud and aggravated identity theft, announced United States Attorney for District of Maryland Rod R. Rosenstein
Source: www.fda.gov

Cefepime (marketed as Maxipime) Update of Ongoing Safety Review
FDA finished its analysis of a possible risk of higher death with cefepime and has determined that the data do not indicate a higher rate of death in cefepime-treated patients.
Source: www.fda.gov

U.S. Attorney News Release: Former Managing Pharmacist Pleads Guilty To Conspiracy to Defraud Health Insurers
The former managing pharmacist at a Middlesex County pharmacy pleaded guilty today to conspiring to defraud health insurers, including the federal Medicaid program, by submitting phony claims for reimbursement for prescription drugs, Acting U.S. Attorney Ralph J. Marra, Jr., announced.
Source: www.fda.gov

FDA Issues Public Health Advisory Regarding Levemir Insulin (Spanish)
La Administración de Medicamentos y Alimentos de los Estados Unidos se ha enterado que algunas ampollas de insulina Levemir de acción prolongada, medicamento elaborado por Novo Nordisk Inc., que habían sido robadas, han aparecido y se encuentran a la venta en los Estados Unidos. El total de ampollas robadas es de 129,000 unidades, lo que equivale a tres lotes del producto. Cabe la posibilidad de que estas ampollas de insulina robadas no hayan sido almacenadas ni manipuladas adecuadamente, lo que puede ser peligroso para los pacientes que la usan.
Source: www.fda.gov

Stimulant Medications used in Children with Attention-Deficit/Hyperactivity Disorder - Communication about an Ongoing Safety Review
FDA provides its perspective on study data published in the American Journal of Psychiatry on the potential risks of stimulant medications used to treat Attention-Deficit/Hyperactivity Disorder in children. The study authors concluded that there may be an association between the use of stimulant medications and sudden death in healthy children.
Source: www.fda.gov

# posted by Network @ 4:58 PM

Subscribe to Posts [Atom]